
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
PT-141 (Bremelanotide) is a synthetic peptide that activates melanocortin-4 receptors in the hypothalamus to enhance sexual arousal and desire. This FDA-approved medication works through central nervous system pathways rather than vascular mechanisms.

Reported Benefits (Provisional)
Origin & History

PT-141, also known as Bremelanotide, is a synthetic peptide derived from the melanocortin receptor agonist family. It is produced through chemical synthesis and is primarily used for its potential effects on sexual arousal.
Research Narrative (Provisional)
PT-141 has been studied in clinical trials for its effects on sexual arousal and erectile dysfunction, showing promising results. Further studies are ongoing.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Composed of a sequence of amino acids. - Administered via subcutaneous injection. - Acts on melanocortin receptors in the brain.
Reported Mechanism (Provisional)
PT-141 selectively binds to melanocortin-4 (MC4R) and melanocortin-1 (MC1R) receptors in the hypothalamic paraventricular nucleus. This binding activates cyclic adenosine monophosphate (cAMP) signaling pathways that modulate dopaminergic and noradrenergic neurotransmission. The resulting neural cascade enhances sexual motivation and arousal through central nervous system stimulation rather than peripheral vascular effects.
Clinical Narrative (Provisional)
Clinical trials included over 1,200 premenopausal women with hypoactive sexual desire disorder (HSDD). Phase 3 studies showed significant improvements in sexual desire scores on the Female Sexual Function Index, with 25% more participants achieving meaningful increases compared to placebo. Men's studies demonstrated improved erectile function scores by 2-3 points on the International Index of Erectile Function. Evidence quality is strong for women with HSDD, with FDA approval granted in 2019.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







